For: | Liu Y. Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future. World J Gastroenterol 2023; 29(34): 5020-5037 [PMID: 37753366 DOI: 10.3748/wjg.v29.i34.5020] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v29/i34/5020.htm |
Number | Citing Articles |
1 |
Rongzhong Wang, Shiyan Wang, Hua Jiang, Yingmei Lan, Shaobin Yu. Prospects for the clinical application of exosomal circular RNA in squamous cell carcinoma. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1430684
|
2 |
Young Seob Shin, Jeong Yun Jang, Ye Jin Yoo, Jesang Yu, Kye Jin Song, Yoon Young Jo, Sung-Bae Kim, Sook Ryun Park, Ho June Song, Yong-Hee Kim, Hyeong Ryul Kim, Jong Hoon Kim. Nomogram for predicting pathologic complete response following preoperative chemoradiotherapy in patients with esophageal squamous cell carcinoma. Gastroenterology Report 2023; 12 doi: 10.1093/gastro/goae060
|
3 |
Chao Zhao, Hui Han, Yushuang Tian, Guangjin Qu, Yingying Xu, Yihan Wang, Lili Shi. Identification of genome-wide copy number variation-driven subtypes for the treatment and prognostic prediction of esophageal carcinoma. Heliyon 2024; 10(19): e38011 doi: 10.1016/j.heliyon.2024.e38011
|
4 |
Shi-Yan Zhang. Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations. World Journal of Gastroenterology 2024; 30(41): 4411-4416 doi: 10.3748/wjg.v30.i41.4411
|
5 |
Jindan Kai, Kai Kang, Zhixiao Jiang, Fei Xiong, Sheng Wang. Capivasertib reverses chemotherapy-induced esophageal cancer resistance via inhibiting Akt-associated Mcl-1 upregulation. Heliyon 2024; 10(13): e33567 doi: 10.1016/j.heliyon.2024.e33567
|
6 |
Yang Yu, Qian Zhao, Hongguang Cui, Liang Song. CCR7 in esophageal squamous cell carcinoma: an identification from single-cell and bulk transcriptome sequencing. Discover Oncology 2025; 16(1) doi: 10.1007/s12672-025-01927-3
|
7 |
Junhan Wu, Xin Xia, Longlong Gong, Shujie Huang, Hongbo Zheng, Guibin Qiao, Yong Tang. Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration. Human Vaccines & Immunotherapeutics 2024; 20(1) doi: 10.1080/21645515.2024.2370085
|
8 |
Nataliya V. Uboha, Mustafa M. Basree, Jens C. Eickhoff, Dustin A. Deming, Kristina Matkowskyj, James Maloney, Daniel McCarthy, Malcolm DeCamp, Noelle LoConte, Philip B. Emmerich, Sean Kraus, Monica A. Patel, Jeremy D. Kratz, Sam J. Lubner, Newton Hurst, Michael F. Bassetti. Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer. Journal of Surgical Oncology 2025; doi: 10.1002/jso.28070
|
9 |
Bo Yang, Wei Gou, Naiying Lan, Qing Shao, Weifeng Hu, Cheng Xue, Nanmei Liu. Tislelizumab induced dual organs dysfunction in a patient with advanced esophageal squamous cell carcinoma: a case report. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1347896
|
10 |
Nuran Bedolla, Linyu Liu, Xueting Liu, Qiuxian Xie, Yanli Ren. Ursolic acid enhances radiosensitivity in esophageal squamous cell carcinoma by modulating p53/SLC7A11/GPX4 pathway-mediated ferroptosis. Toxicon 2025; 255: 108233 doi: 10.1016/j.toxicon.2025.108233
|
11 |
Zhengzhou Qiu, Zhao Li, Xingfei Liu, Ruilin Zhang, Yongxuan Li, Chenggen Gao, Xiaoling Mao, Yin Bao, Mingyue Zhang, Changying Guo. From tumor microenvironment to emerging biomarkers: the reshaping of the esophageal squamous cell carcinoma tumor microenvironment by neoadjuvant chemotherapy combined with immunotherapy. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1478922
|
12 |
Mohamed Wishahi. Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept. World Journal of Hepatology 2024; 16(4): 490-493 doi: 10.4254/wjh.v16.i4.490
|